{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:08:02Z","timestamp":1789729682113,"version":"4.0.1"},"reference-count":31,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Veterinary Record"],"published-print":{"date-parts":[[2026,9,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of this study was to report tolerability, safety and outcome in dogs with malignant epithelial rectal tumours receiving piroxicam suppositories where curative\u2010intent surgery was not performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medical records from one UK referral hospital were retrospectively searched for dogs with malignant epithelial rectal tumours receiving piroxicam suppositories. Dogs receiving curative\u2010intent surgery or anti\u2010cancer agents were excluded. The primary outcomes were owner\u2010reported improvement in clinical signs and veterinarian\u2010assessed cRECIST (canine Response Evaluation Criteria for Solid Tumours) responses. The secondary outcomes recorded included overall survival time and progression\u2010free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eight dogs were reported. Four patients experienced owner\u2010reported clinical benefit, characterised by partial (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a02) or complete (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a02) resolution of clinical signs. Among these, three dogs had stable disease, and one dog achieved a complete response. Drug toxicity included hypersalivation (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a01), vomiting (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a02), elevations in renal markers (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a02) and oliguric acute kidney injury (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a01); the latter occurred 1248 days into therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitations<\/jats:title>\n                    <jats:p>The small number of animals, owner\u2010reported outcomes, non\u2010standardised treatments and limited follow\u2010up may affect the interpretation of the findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Piroxicam suppositories improve clinical signs and may stabilise or reduce tumour volume in some dogs with rectal carcinomas where curative\u2010intent surgery is not performed. Regular serum biochemistry monitoring is recommended due to the potential for renal toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/vetr.70170","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T04:05:09Z","timestamp":1766030709000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and toxicity of piroxicam rectal suppositories in palliative management of rectal carcinoma in dogs not receiving curative\u2010intent surgery: A retrospective case series of eight dogs"],"prefix":"10.1002","volume":"199","author":[{"given":"Isabelle","family":"Ng","sequence":"first","affiliation":[{"name":"Department of Oncology Pride Veterinary Referrals  Derby UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Oncology Pride Veterinary Referrals  Derby UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.250.4.424"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.1987.tb05974.x"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.5326\/15473317-33-2-156"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.1987.191.06.727"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.2000.tb03230.x"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.245.6.684"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/vsu.13766"},{"issue":"1","key":"e_1_2_11_9_1","first-page":"12","article-title":"Outcome of dogs treated with toceranib phosphate for colorectal carcinoma. 9 cases (2016\u20122022). In: Abstracts from the ESVONC Annual Congress 2023","volume":"22","author":"Sosa VS","year":"2024","journal-title":"Vet Comp Oncol"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.239.2.222"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686255"},{"issue":"2","key":"e_1_2_11_12_1","first-page":"356","article-title":"Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer","volume":"62","author":"Mohammed SI","year":"2002","journal-title":"Cancer Res"},{"issue":"1","key":"e_1_2_11_13_1","first-page":"87","article-title":"Piroxicam pharmacologic activity and gastrointestinal damage by oral and rectal route: comparison with oral indometacin and phenylbutazone","volume":"31","author":"Schiantarelli P","year":"1981","journal-title":"Arzneimittel\u2010Forschung"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.2006.00006.x"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.2006.00094.x"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2017.02.001"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.2000.tb03141.x"},{"issue":"4","key":"e_1_2_11_18_1","first-page":"744","article-title":"Piroxicam capsules versus suppositories: a pharmocokinetic and clinical trial","volume":"36","author":"A\u00e4rynen M","year":"1986","journal-title":"Arzneimittel\u2010Forschung"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/030098588001700204"},{"key":"e_1_2_11_20_1","first-page":"460","volume-title":"Withrow & MacEwen's small animal clinical oncology","author":"Selmic L","year":"2020"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.283"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12032"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.12127"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.5326\/JAAHA-MS-6637"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.2460\/AJVR.2002.63.91"},{"key":"e_1_2_11_26_1","volume-title":"BSAVA small animal formulary","author":"Ramsey I","year":"2014"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007999509110494"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.259.4.385"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.1994.tb03232.x"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.5326\/JAAHA-MS-6239"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-2995.2011.00675.x"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.241.10.1314"}],"container-title":["Veterinary Record"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bvajournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/vetr.70170","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bvajournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/vetr.70170","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bvajournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/vetr.70170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:48:16Z","timestamp":1789728496000},"score":1,"resource":{"primary":{"URL":"https:\/\/bvajournals.onlinelibrary.wiley.com\/doi\/10.1002\/vetr.70170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9,19]]}},"alternative-id":["10.1002\/vetr.70170"],"URL":"https:\/\/doi.org\/10.1002\/vetr.70170","archive":["Portico"],"relation":{},"ISSN":["0042-4900","2042-7670"],"issn-type":[{"value":"0042-4900","type":"print"},{"value":"2042-7670","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}